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Background:The approval of immune checkpoint inhibitors in combination with specific
diagnostic biomarkers presents new challenges to pathologists as tumor tissue needs
to be tested for expression of programmed death-ligand 1 (PD-L1) for a variety of
indications. As there is currently no requirement to use companion diagnostic assays for
PD-L1 testing in Germany different clones are used in daily routine. While the correlation
of staining results has been tested in various entities, there is no data for head and neck
squamous cell carcinomas (HNSCC) so far.
Methods: We tested five different PD-L1 clones (SP263, SP142, E1L3N, 22-8, 22C3)
on primary HNSCC tumor tissue of 75 patients in the form of tissuemicroarrays. Stainings
of both immune and tumor cells were then assessed and quantified by pathologists to
simulate real-world routine diagnostics. The results were analyzed descriptively and the
resulting staining pattern across patients was further investigated by principal component
analysis and non-negative matrix factorization clustering.
Results: Percentages of positive immune and tumor cells varied greatly. Both the
resulting combined positive score as well as the eligibility for certain checkpoint inhibitor
regimens was therefore strongly dependent on the choice of the antibody. No relevant
co-clustering and low similarity of relative staining patterns across patients was found for
the different antibodies.
Conclusions: Performance of different diagnostic anti PD-L1 antibody clones in HNSCC
is less robust and interchangeable compared to reported data from other tumor entities.
Determination of PD-L1 expression is critical for therapeutic decision making and may
be aided by back-to-back testing of different PD-L1 clones.
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INTRODUCTION
In a growing number of solid tumors, immunotherapy by
checkpoint blockage targeting programmed death receptor 1
(PD-1) or its ligand programmed death-ligand 1 (PD-L1)
has become a standard treatment (1–9). The response to
the administration of most PD-1 or PD-L1 inhibitors often
correlates with PD-L1 expression determined before therapy
using specific companion diagnostics for immunohistochemistry
(IHC) resulting in approval in combination with PD-L1
expression as a diagnostic biomarker (8, 9). In HNSCC, this
does not hold good for nivolumab which is approved for
administration after cisplatin failure, regardless of PD-L1 status
determined by IHC. For pembrolizumab, though, it is still
necessary to specify PD-L1 status by IHC. Interestingly, most
tumor boards still request PD-L1 status from the pathologists
to decide for or against a checkpoint inhibitor therapy regime.
While IHC is a routine tool in modern pathology to investigate
diagnostic and predictive markers in tissue samples, its use in
PD-L1 expression analysis has raised several issues: (a) There are
different PD-L1 assays each specific to a therapeutic antibody
without a common standard. (b) Different scoring systems are
applied to different tumor types and indications. (c) Problems of
tumor heterogeneity, inter-institutional preanalytics, and inter-
/intra-observer variability are being addressed but are difficult
to solve (10). Several attempts have been made to compare
commercially available PD-L1 clones (11–14). For example, clone
22C3 (Agilent Dako Omnis, Santa Clara, CA, USA) showed
high concordance with SP263 (Ventana Medical Systems Roche,
Oro Valley, AZ, USA). For non-small cell lung cancer (NSCLC),
it was therefore recently CE-marked for interchangeable use
with 22C3 and 28-8 (Abcam, Cambridge, UK) (10). Some
pathology laboratories use less expensive PD-L1 clones such as
22C3 and E1L3N for different reasons. Like many hospitals,
they are dedicated to the economically efficient use of reagents
and resources. Similarly, some lack access to the specific
immunostainer platform that is necessary to carry out clone-
specific stains (e.g., Ventana Benchmark immunostainer for
SP263, both Ventana Roche), and there are no commercially
available ready to use kits for PD-L1 clones for the widely used
Leica Bond platform (Leica Biosystems, Wetzlar, Germany) (10).
Checkpoint and PD-L1 inhibitors like pembrolizumab,
atezolizumab, and durvalumab have been approved for first
or second-line treatment of PD-L1 positive advanced cancers
[e.g., NSCLC (2, 3, 15)], urothelial cancer (16), and triple-
negative breast cancer (17). Since then, pathologists are
required to report the PD-L1 status, which comprises one
or more PD-L1 scores depending on the tumor entity. The
tumor positivity score (TPS) is defined as the estimated
percentage of tumor cells showing partial or complete
membrane staining for PD-L1. It was developed for clone
22C3 as a biomarker for pembrolizumab (9, 18). The immune
cell score (IC) is based on the estimated area of PD-L1
positive tumor immune cells in relation to all tumor immune
cells. It was developed for SP142 in urothelial carcinoma,
NSCLC (15), and TNBC. The combined positivity score
(CPS) is supposed to reflect both tumor cell and immune
cell PD-L1 expression. It was also developed as a biomarker
for pembrolizumab.
In the USA, the Federal Drug Administration (FDA) restricted
the application of pembrolizumab for advanced NSCLC to those
patients whose tumor samples had been tested using the DAKO
22C3 pharmDx assay (the so-called companion diagnostic assay)
(18). In Europe though, the DAKOplatform is not as widely used,
and the European Medicines Agency (EMA) does not demand a
mandatory specific PD-L1 IHC platform or clone (10).
For recurrent HNSCC, two therapeutic anti-PD-1 antibodies
are currently used: Nivolumab after cisplatin failure without PD-
L1 expression as a biomarker and Pembrolizumab after cisplatin
failure and with a TPS ≥50%. Pembrolizumab is also approved
for palliative first-line treatment of HNSCC with a CPS≥1
with or without platinum-based chemotherapy. Thus, targeting
the same molecule, Pembrolizumab requires PD-L1 expression
to be demonstrated by IHC, while the use of Nivolumab is
not restricted.
MATERIALS AND METHODS
Tumor Material and Patient Data
The study was conducted according the Declaration of Helsinki.
Approval by the University of Luebeck Ethics Committee
was obtained (project code AZ 16-277). Tissue samples were
routinely fixated in 4% buffered neutral formalin for 12–24 h.
After paraffin embedding the preserved tissue blocks were stored
at room temperature in our archives until they were retrieved.
We accessed our large and comprehensively clinicopathologically
characterized HNSCC cohort, as described before (19, 20). For
the study at hand, we selected those TMAs from our cohort
that contained tumor tissue of recurrent disease and matching
primary tumors (n= 75 patients). For patient details please refer
to Supplementary Table 1.
TMA Construction
H&E slides were annotated for regions of interest (ROI)
containing representative squamous cell carcinoma areas.
Corresponding paraffin blocks were matched. Manual Tissue
Arrayer 1 (Estigen AlphaMetrix Biotech, Rödermark, Germany)
was used to construct TMAs as seen in Figure 1. Briefly, 2mm
diameter cores were punched out of the donor block’s ROI and
embedded into a paraffin recipient block. This was repeated three
times for each tumor sample resulting in three cores per patient.
One recipient block holds up to 60 triplets. Whenever possible,
meaning whenever enough representative tumor tissue could be
yielded, we created two more replicas of each TMA.
Immunohistochemistry and Evaluation
of Stains
3µm thin slices were cut from the TMA recipients’ blocks
and put on glass slides (Figure 1). All immunohistochemical
stainings were performed on a Ventana BenchMark automated
staining system (Roche, Basel, Switzerland), as previously
described (21). Deparaffinization protocol according to EZ Prep
was followed by heat-mediated antigen retrieval (pH 8.4 buffer
for up to 32min; both Ventana Medical Systems Roche, Oro
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Valley, AZ, USA). Primary antibody was titrated and incubated
as follows.
- SP263: incubation for 20min at 36◦ (rabbit monoclonal
antibody with OptiView DAB IHC Detection Kit, both
Ventana Medical Systems Roche)
- SP142: incubation for 8min at 37◦ (rabbit monoclonal
antibody with OptiView DAB IHC Detection Kit, both
Ventana Medical Systems Roche)
- E1L3N: incubation for 60min at 36◦ (rabbit monoclonal
antibody, RTU, Cell Signaling, Danvers, MA, USA).
Counterstaining with haematoxylin (Ventana Medical
Systems, Tucson, AZ, USA) and the proper alkalinity was
ensured by washing with Bluing reagent, pH= 8.0.
- 28-8: incubation for 40 minutes at 37◦ (ab205921, rabbit
monoclonal antibody, Abcam, Cambridge, UK with OptiView
IHC Detection Kit, Ventana Medical Systems Roche)
FIGURE 1 | Construction of tissue microarray. Donor H&E slides were
annotated for the tumor region. The matching donor blocks were identified
and annotated as well. Three cores from the region of interest were punched
out and embedded in the recipient paraffin block. The recipient block could
then serve for multiple analyses, e.g., immunohistochemical stainings.
- 22C3: incubation for 40min at 37◦ (mouse monoclonal
antibody, Agilent Dako Omnis, Santa Clara, CA, USA
with OptiView DAB IHC Detection Kit, Ventana Medical
Systems Roche)
Tonsil tissue was employed as positive control
(Supplementary Figure 1). PD-L1 IHC stains were then
evaluated by two independent pathologists. Tumors were
represented by three cores to address tumor heterogeneity.
PD-L1 scores were reported separately for each core. Mean
values of the three cores were calculated and used as input
for score calculation. The resulting expression data contained
the number and area shares of tumor and immune cells
with the expression as well as the ratio of tumor to immune
cell number [necessary to calculate the combined positive
score (CPS)]. The latter was calculated as the number of
positive immune and tumor cells divided by the number
of viable tumor cells, multiplied by and capped at 100. The
total positive score (TPS) was calculated as the percentage of
tumor cells with positive membrane staining, regardless of
staining intensity and continuance. The immune cell score
(IC) is the percentage of tumor area occupied by tumor
immune cells.
Statistical Analysis and Visualization
All statistical analyses were performed by custom scripts in
Python 2.7 (Enthought, Austin, USA, Canopy distribution
1.1.0.1371) including the scipy, numpy, sklearn, matplotlib,
seaborn and pandas packages. Non-negative matrix
factorization was performed based on the nimfa package
(22). Briefly, the data were z-score transformed, shifted
by the minimum value to turn negative into positive
values without changing data patterns, and factorized with
random seed, rank ∗ 100 iterations and 100 runs. The
resulting data was further analyzed and visualized with the
scipy.cluster.hierarchy module.
FIGURE 2 | PD-L1 staining pattern in HNSCC. Upper row: tumor cells. Lower row: immune cells. From left to right: 22C3, 28-8, E1L3N, SP142, and SP263. Original
magnification x100. Inlay magnification x200.
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FIGURE 3 | Qualitative results. (A,B): Patients were ranked by their mean positive tumor and immune cells respectively to facilitate comparison across the different
antibody clones; (C): The combined positive score (CPS) was calculated for each patient and the resulting eligibility for pembrolizumab portrayed in binary
representation (color = eligible) (D).
Apart from Python visualization packages, we used
the following software to create artwork and edit
photomicrographs. Inkspace (version 0.92.4, The Inkscape
Project c/o Software Freedom Conservancy, Brooklyn, NY,
USA, https://inkscape.org/), Krita (version 4.2.8, Stichting
Krita Foundation, Deventer, The Netherlands, https://
krita.org), GIMP (version 2.10.14, The GIMP Project c/o
GNOME Foundation, Orinda, CA, USA, https://www.gimp.
org).
RESULTS
Tumor Material and Patient Data
As described previously, our cohort is well-representative for
HNSCCs and well-reflects the aggressive tumor behavior (19).
Briefly, our cohort mirrors the typical characteristics for HNSCC
patients: three-quarters were men with smoking and alcohol
as common nutritive-toxic pathogens. A little <1/3 were p16
positive. The majority offered advanced stages (UICC III/IV) at
first-time diagnosis. About 25% of patients experienced a cancer
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FIGURE 4 | Principal component analysis and rank estimate for non-negative matrix factorization (NMF) consensus clustering. (A): Principal components were
calculated for the dataset and the individual clones visualized two-dimensionally according to their relative correlation with the two main components; (B): In NMF the
cophenetic correlation was calculated to find the number of clusters that reduced dimensionality best.
relapse, half of which passed away within 5 years. The 5-year
survival for the whole cohort was about 60%.
Immunohistochemistry and Evaluation
of Stains
We performed immunohistochemical PD-L1 stains for five
clones (22C3, 28-2, E1L3N, SP142, and SP263) and estimated
TPS, IC, and CPS. All five clones delivered satisfactory staining
quality with 22C3 being the most discreet. SP142 offered a more
grainy aspect. E1L3N, SP263, and 28-8 showed a robust pattern
(Figure 2). Positive controls demonstrate staining success (tonsil
tissue, Supplementary Figure 1).
Statistical Analysis
To illustrate the variety of staining with different clones, the
mean share of positive stainings across clones was calculated and
the patient samples ranked by this order (Figures 3A,B). The
resulting distribution showed marked dispersion, which was also
mirrored by the resulting CPS (Figure 3C). As a relevant clinical
consequence, the individual eligibility of patients for first-line
pembrolizumab was assessed by CPS ≥ 1 (Figure 3D). Thereby,
relevant differences between clones were observed with eligible
patients ranging from SP142 with 14%, 22C3 with 18% to E1L3N
with 48%, SP263 with 68%, and 28-8 with 78% of patients.
As other cutoffs are used in clinical trials we also calculated
alternative eligibility cutoffs for CPS1, CPS20, CPD50, and TPS50
(Supplementary Figure 2).
Apart from this qualitative assessment, the identification of
underlying staining patterns was approached by principal
component analysis (PCA) and non-negative matrix
factorization-based consensus clustering (NMF). While PCA
showed similarity between the tumor stainings of SP142, 22C3,
and E1L3N (Figure 4A), no stable and relevant reduction of
dimensionality could be observed by NMF clustering (Figure 5)
indicated by maximum cophenetic correlation for k = 10
clusters (with n = 10 input samples (clones); Figure 4B). Some
co-clustering of SP142/22C3 tumor staining was observed as well
as less stable co-clustering of SP263 and E1L3N tumor staining.
SP263 and 28-8 co-clustered relatively strongly for k= 2 clusters,
mirrored by similar correlations in PCA and similar quantitative
results of the staining raw data. However, the cluster did not
prove to be stable in higher ranks (compare to quick drop in
cophenetic correlation, Figure 4B).
DISCUSSION
The introduction of immune checkpoint inhibitors in cancer
therapy considerably improved survival in several entities, e.g.,
melanoma and lung cancer (23, 24). For HNSCC, survival
improved compared to the previous standard of care. However,
the high hopes remained hitherto unfulfilled in large part. While
overall survival for recurrent disease is still significantly increased
in comparison with previous therapy regimens, the effect size
seems to be smaller than in melanoma (8, 25). Adverse effects
were significantly less severe than with chemotherapy. No more
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FIGURE 5 | NMF consensus clustering. For varying numbers of clusters (ranks; subplots), NMF consensus clustering was performed; for each rank, the consensus
matrix as a measure of cluster stability is shown as a heat plot with red indicating perfect consensus for a given pair of clones across stochastic runs (the clones end
up in the same cluster all the time); the dendrogram on the left indicates relative cluster similarity by the respective lengths of the horizontal lines.
grade IV/V side effects were observed than with the comparator.
Still, checkpoint inhibitors do offer side effects, some of which
can be quite severe (e.g., pneumonitis, myocarditis). Against this
background accurate checkpoint inhibitor response prediction in
HNSCC patients is important.
Our data show a marked variation of staining results based
on the diagnostic antibody used. Both descriptive analyses
such as the basic share of positive cells as well as more
comprehensive statistical approaches reveal only weak staining
similarity, mostly between SP263 and 28-8 tumor staining.
Taken altogether this translates into considerably different
shares of patients being identified as eligible for second-
line monotherapy.
Several harmonization studies for the diagnostic detection
of PD-L1 expression were performed in different solid cancer
entities with most studies focusing on non-small cell lung
cancer (12, 14, 26–30). The results of the study presented
here are only partially mirrored by investigations in other
tumor entities. In two large studies of PD-L1 staining in
lung cancer, three out of four assays showed interchangeable
results (11, 31). In urothelial carcinoma, the different antibodies
directed against PD-L1 showed different staining positivities but
variance was still confined to an acceptable level. Here, too,
three out of four assays were virtually interchangeable (32).
In the above-mentioned studies, SP142 stained fewer samples,
which was also observed in our data with SP142 identifying
the fewest patients to be eligible for Pembrolizumab with
CPS ≥ 1. In our study, the 22C3 clone showed CPS> = 1
in surprisingly much <85% reported in the KEYNOTE-048
(8) study. This may be due to tumor heterogeneity, selection
bias, different pre-analytics, or staining platform protocols.
Whatever the reason, this stark contrast further encourages to
be cautions upon PD-L1 scoring results. Other comparative
studies in non-small cell lung cancer found a high concordance
in tumor cell scores for PD-L1 but apoor concordance in
immune cells. Similarly, our results demonstrate slightly better
concordance in tumor cell scoring compared to immune cells,
which might affect CPS variance overproportionally. Overall
comparability of scoring performance, however, was much
lower in our data regardless of cell type than described in
other entities.
The deviation of our results may in part root in the approach
taken: To stay as close to real-world routine diagnostics as
possible we did not average the results by multiple reviewing
pathologists. The pronounced staining heterogeneity nonetheless
suggests further systemic differences compared to other tumor
entities. In this context, a potentially relevant aspect has been
addressed by Lee et al. showing differences in the binding of Dako
28-8 before and after deglycosylation of FFPE samples (33). They
concluded that the binding of a diagnostic antibody directed
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against PD-L1 is affected by the glycosylation state of the PD-L1
molecule itself. Since every antibody binds to a different epitope
of the PD-L1 molecule, binding can be differentially affected by
the glycosylation status of PD-L1 in each sample. Different levels
of the inter-tumor variance of glycosylation patterns in HNSCC
and other tumorsmight explain our observations—at least for the
diagnostic antibodies that bind to the N-terminal extracellular
domain [28-8 and 22C3; (34)].
Apart from discussing fixed diagnostic/therapeutic antibody
pairs as companion diagnostic assays, it might be necessary
to take a closer look at preanalytical optimization. Different
glycosylation patterns in turn might not only be relevant in
blurring formal eligibility criteria but also in better prediction
of actual tumor biological behavior (33, 35). The different
diagnostic scores in use add further complexity but only the
CPS is currently applied clinically in HNSCC. We therefore
restricted our primary comparisons to the CPS, with similar
results for the TPS (Supplementary Figure 1). Given our present
data, CPS determination in HNSCC should be interpreted
with caution for therapeutic decisions. As CPS is crucial for
therapeutic decision making a conceivable solution may be
to establish an algorithm of testing various PD-L1 clones in
succession to determine the CPS. In a back-to-back testing
sequence, different PD-L1 clones could compensate for each
other’s “blind spots.”
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Supplementary Figure 1 | Positive control for PD-L1 immunohistochemistry.
Tonsil tissue, from top to bottom: 22C3, 28-8, E1L3N, SP142, and SP263.
Original magnification x100. Inlay magnification x400.
Supplementary Figure 2 | Clinical eligibility for alternative CPS and TPS cutoffs.
(A) CPS 1 eligibility. (B) CPS 20 eligibility. (C) CPD50 eligibility. (D) TPS 50 eligibility.
Supplementary Table 1 | Patient Data.
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